Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | EED | O75530 | 1/20 | 0.46 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.46 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.46 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | TYMP | P19971 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PNP | P00491 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2591808 | 0.98 | MEN1 (0.46) | MEN1KMT2AL3MBTL1EEDRBBP4 | |
| SCHEMBL18708623 | 0.86 | EED (0.47) | MEN1KMT2AL3MBTL1EEDRBBP4 | |
| SCHEMBL14760449 | 0.81 | KMT2A (0.48) | MEN1KMT2AL3MBTL1EEDRBBP4 | |
| SCHEMBL14716843 | 0.80 | EED (0.60) | EEDRBBP4SUZ12AEBP2PDE3B | |
| SCHEMBL18469670 | 0.80 | EED (0.39) | MEN1KMT2AL3MBTL1EEDRBBP4 | |
| SCHEMBL2594097 | 0.79 | KDM4E (0.46) | MEN1KMT2AL3MBTL1PDE3BPDE3A | |
| SCHEMBL9277706 | 0.78 | KMT2A (0.46) | MEN1KMT2AL3MBTL1EEDRBBP4 | |
| Hydrochloric Acid SCHEMBL2591197 | 0.77 | KDM4E (0.45) | MEN1KMT2AL3MBTL1PDE3BPDE3A | |
| SCHEMBL2594511 | 0.76 | PARP1 (0.50) | MEN1KMT2AL3MBTL1ALDH1A1KDM4E | |
| SCHEMBL2591427 | 0.75 | EED (0.46) | MEN1KMT2AL3MBTL1EEDRBBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10478426-B2 | Enhancer of Zeste Homolog 2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2019-11-19 | — | — | US | disclosed |
| US-10478426-B2 | Enhancer of Zeste Homolog 2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2019-11-19 | — | — | US | disclosed |
| US-20180207144-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE LLC | 2018-07-26 | — | — | US | disclosed |
| US-20180207144-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE LLC | 2018-07-26 | — | — | US | disclosed |
| US-20180207144-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE LLC | 2018-07-26 | — | — | US | disclosed |
| US-9956210-B2 | Enhancer of zeste homolog 2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2018-05-01 | — | — | US | disclosed |
| US-9956210-B2 | Enhancer of zeste homolog 2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2018-05-01 | — | — | US | disclosed |
| US-9956210-B2 | Enhancer of zeste homolog 2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2018-05-01 | — | — | US | disclosed |
| EP-3246027-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF CANCER | GlaxoSmithKline LLC (US) | 2017-11-22 | — | — | EP | disclosed |
| EP-3246027-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF CANCER | GlaxoSmithKline LLC (US) | 2017-11-22 | — | — | EP | disclosed |
| US-20130053383-A1 | INDAZOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
| US-20130053397-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
| US-20130053383-A1 | INDAZOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
| US-20130053383-A1 | INDAZOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
| WO-2012075080-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2012-06-07 | — | — | WO | disclosed |
| WO-2012075080-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2012-06-07 | — | — | WO | disclosed |
| WO-2011140324-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011140325-A1 | INDAZOLES | GLAXOSMITHKLINE LLC (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011140325-A1 | INDAZOLES | GLAXOSMITHKLINE LLC (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011140324-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053383-A1 | INDAZOLES | IDH3A, CYP3A7, IDH3B | MEN1 1306/4885KMT2A 2540/4885L3MBTL1 2754/4885 |
| US-20180207144-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | EZH2, EZH1, BMI1 | MEN1 673/4885KMT2A 18/4885L3MBTL1 2641/4885 |
| US-10478426-B2 | Enhancer of Zeste Homolog 2 inhibitors | EZH2, EZH1, BMI1 | MEN1 673/4885KMT2A 18/4885L3MBTL1 2641/4885 |
| US-20130053397-A1 | INDOLES | IDO1, IDO2, INMT | MEN1 795/4885KMT2A 933/4885L3MBTL1 3210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.